Latest Articles, News & Analysis on biotech

March 19, 2015 06:52

Trend alert: Last year saw the biggest overall increase in prescription drug spending in the US since 2003

Livewire Equities

Livewire

March 19, 2015 06:52

December 05, 2014 15:37

Yesterday's Australia Biotech Invest 2014 conference in Melbourne rather optimistically considered whether the flight from resources stocks may benefit the...

John Robertson

PortfolioDirect

December 05, 2014 15:37

July 24, 2014 07:09

3 short-term Biotech plays

Livewire Equities

Livewire

July 24, 2014 07:09

June 24, 2014 13:42

Bionomics (BNO) - Merck thinks BNC375 is unforgettable, too | Analyst: Stuart Roberts | Rating: Buy TP:$1.10 | Bionomics has secured a new research...

Mathan Somasundaram

Deep Data Analytics

June 24, 2014 13:42

April 29, 2014 09:01

David Merkel from the Aleph Blog says It is wise to avoid the area of the market where issuance is well above average

Livewire News

Livewire

April 29, 2014 09:01

April 15, 2014 00:50

The US transport sector and the biotech sector are two extremes of the US market

John Robertson

PortfolioDirect

April 15, 2014 00:50

April 11, 2014 05:09

There's some interesting action going on in US equities today

Jay Soloff

Argonath Financial

April 11, 2014 05:09

April 10, 2014 15:21

At least one patient with diabetic limb ulcers will be pleased that they participated in Osprey Medical's (ASX:OSP) Limb Recovery trial

Matthijs Smith

Canaccord Genuity Australia

April 10, 2014 15:21

April 07, 2014 11:30

After Prana (ASX:PBT) announced a result we would rather forget from their Alzheimer's drug, the biotech sector closed down 7.9% last week

Matthijs Smith

Canaccord Genuity Australia

April 07, 2014 11:30

March 25, 2014 12:31

dorsaVi (ASX:DVL) is walking around with an impressive update on the commercialisation of its movement products

Matthijs Smith

Canaccord Genuity Australia

March 25, 2014 12:31

March 11, 2014 13:31

Last week, the small end of town was where all the action was in biotech-land with Biotron (ASX:BIT) up 97%, newcomer Innate Therapeutics (ASX:IIL) up 33% and...

Matthijs Smith

Canaccord Genuity Australia

March 11, 2014 13:31

February 05, 2014 17:38

Morgans Research maintain an add recommendation on GI Dynamics (GID) with a price target of $1.61

Livewire Equities

Livewire

February 05, 2014 17:38

January 28, 2014 09:55

Innate Immunotherapeutics (IIL) listed late in 2013 with Australian Ethical taking a cornerstone position in the float

Livewire Equities

Livewire

January 28, 2014 09:55

61-73 of 73

Equities

Silver set for its day in the sun courtesy of solar panel boom

Barry FitzGerald,

Independent Journalist

Equities

2 undiscovered stocks (and how to analyse under-the-radar companies)

Buy Hold Sell,

Livewire Markets

Equities

How to identify consistent compounders (and 17 stocks that make the cut)

Ally Selby,

Livewire Markets

Equities

Macquarie tips these 6 ASX stocks could outperform

Sara Allen,

Livewire Markets

Account

Company

biotech

Trend alert: Last year saw the biggest overall increase in prescription drug spending in the US since 2003

Yesterday's Australia Biotech Invest 2014 conference in Melbourne rather optimistically considered whether the flight from resources stocks may benefit the...

3 short-term Biotech plays

Bionomics (BNO) - Merck thinks BNC375 is unforgettable, too | Analyst: Stuart Roberts | Rating: Buy TP:$1.10 | Bionomics has secured a new research...

David Merkel from the Aleph Blog says It is wise to avoid the area of the market where issuance is well above average

The US transport sector and the biotech sector are two extremes of the US market

There's some interesting action going on in US equities today

At least one patient with diabetic limb ulcers will be pleased that they participated in Osprey Medical's (ASX:OSP) Limb Recovery trial

After Prana (ASX:PBT) announced a result we would rather forget from their Alzheimer's drug, the biotech sector closed down 7.9% last week

dorsaVi (ASX:DVL) is walking around with an impressive update on the commercialisation of its movement products

Last week, the small end of town was where all the action was in biotech-land with Biotron (ASX:BIT) up 97%, newcomer Innate Therapeutics (ASX:IIL) up 33% and...

Morgans Research maintain an add recommendation on GI Dynamics (GID) with a price target of $1.61

Innate Immunotherapeutics (IIL) listed late in 2013 with Australian Ethical taking a cornerstone position in the float

most popular

Equities

Silver set for its day in the sun courtesy of solar panel boom

Equities

2 undiscovered stocks (and how to analyse under-the-radar companies)

Equities

How to identify consistent compounders (and 17 stocks that make the cut)

Equities

Macquarie tips these 6 ASX stocks could outperform

view all